<DOC>
	<DOCNO>NCT03055845</DOCNO>
	<brief_summary>A phase I , randomize , double-blinded , placebo-controlled , single ascend dose study investigate safety , local tolerability transformation nucleus pulposus follow intradiscal injection STA363 placebo patient discogenic low back pain . 15 patient participate either 3 dose group , comprise 5 patient : - Group 1 : STA363 dose 1 ( 3 patient ) placebo ( 2 patient ) - Group 2 : STA363 dose 2 ( 3 patient ) placebo ( 2 patient ) - Group 3 : STA363 dose 3 ( 3 patient ) placebo ( 2 patient )</brief_summary>
	<brief_title>A Single Ascending Dose Study Safety Tolerability STA363 Compared Placebo 15 Patients With Chronic Discogenic Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>Signed informed consent prior studyrelated procedure Chronic discogenic low back pain present 6 month prior screen visit 20 60 year age screen visit Insufficient response least 6 month nonoperative treatment ( analgesic and/or antiinflammatory medication , physiotherapy etc . ) A single lumbar disc appropriate treatment L3/4 L5/S1 , base clinical evaluation investigator Pfirrmann grade IIIII Ability understand write verbal information study Treatment investigational product within 3 month prior screen visit More one painful intervertebral disc A painful intervertebral disc L3/4 level Current infection prior history spinal infection ( e.g. , discitis , septic arthritis , epidural abscess ) active systemic infection Previous lumbar spine surgery Previous disc invasive treatment procedure affect level ( ) ( e.g. , intradiscal electrothermal therapy , intradiscal radiofrequency thermocoagulation ) Pfirrmann grade I , IV V Evidence prior lumbar vertebral body fracture trauma Need spinal decompression assess investigator Presence disc extrusion sequestration Patients previously include study Patients suffer psychosomatic pain opinion investigator Referred leg pain compressive origin Known alcohol and/or drug abuse Severe intercurrent illness ( e.g . rheumatic disease chronic pain syndrome ) concomitant treatment ( e.g . immunosuppressive drug ) , , opinion investigator , may put patient risk participate study , affect patient 's ability take part study Clinically significant abnormality clinical chemistry haematology parameter assess investigator Pregnant lactating female intention become pregnant within study period Known allergy component drug product placebo Known opioid allergy intolerance Patients require treatment warfarin anticoagulant therapy Unwillingness refrain treatment nonsteroidal antiinflammatory drug ( NSAIDs ) within 5 day plan study treatment Body weight less 50 kg</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>